Question explored with the scientific record
ozimpec side effects
The retrieval for "ozimpec" surfaced nothing about it. Every record is about a different drug, so I cannot tell you its side effects from evidence.
I don't recognize "ozimpec" as a drug name. It may be a misspelling of Ozempic (semaglutide), or of something else entirely. I won't guess and then hand you side effects for a drug you didn't ask about.
What came back is a set of studies on monoclonal antibodies: daratumumab, ocrelizumab, cetuximab, donanemab, and others [1][2][3][4]. Those are infusion drugs for cancer and MS. None of them is ozimpec, whatever it is. Citing them here would be worse than saying nothing.
If you meant Ozempic, tell me and I'll answer for semaglutide specifically. If "ozimpec" is a real product name, give me the generic name or what condition it treats, and I can work from that.
My call: I can't answer this one. The name doesn't match anything in the evidence, and inventing a drug profile would be the exact failure you're here to avoid. Confidence: not clear, because the question and the evidence don't meet.
Sources used 4
-
Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System
A retrospective pharmacovigilance study of FAERS (2015–2023) characterizing neuropsychiatric adverse events associated with monoclonal antibodies approved for multiple myeloma, identifying disproportional reporting signals such as cerebral infarction, stroke, delirium, GBS, and …
DOI: 10.3390/ph17101266 -
PO130 A case of neuromyelitis optica spectrum disease, necrotizing myositis and breast cancer
A pooled safety analysis of ocrelizumab in OPERA I/II and ORATORIO shows infusion-related reactions are the most common adverse events, more frequent with ocrelizumab than comparators, especially at first infusion, generally mild to moderate, and decreasing over subsequent infus…
DOI: 10.1136/jnnp-2017-abn.160 -
Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
This study conducts a pharmacovigilance analysis of adverse events associated with amivantamab in patients with EGFR exon 20 insertion mutations in non-small cell lung cancer, revealing a significant toxicity profile primarily characterized by infusion-related reactions and derm…
DOI: 10.1186/s12890-025-03509-z -
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
This study investigates the presence of IgE antibodies against cetuximab, a monoclonal antibody used in cancer treatment, and their association with hypersensitivity reactions, revealing that many patients had preexisting antibodies specific for galactose-α-1,3-galactose before …
DOI: 10.1056/NEJMOA074943